ALDEYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.2 USD | +6.60% |
|
+6.60% | +19.66% |
| 25/04 | Transcript : Aldeyra Therapeutics, Inc. - Special Call | |
| 04/04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Chart calendar Aldeyra Therapeutics, Inc.
da72fc8ae963.a7dwpBOPhWIPjJlYR6QCxSCStP3TQJvznP3QuEFfM84.H9ID8H_3yTJcxvY3FddhtxHk2KKaccnC0Lrh1XEVdr4kz13qYunfCjbOwA~c2107759a7539283216bf99f0a549b0b
Past events on Aldeyra Therapeutics, Inc.
| Today | Q1 2024 Earnings Release (Projected) |
| 25/04/2024 06:30 pm | Research & Development Day |
| 28/03/2024 05:30 pm | Business Update Call |
| 14/02/2024 02:30 am | Oppenheimer Healthcare Life Sciences Conference |
| 19/12/2023 06:30 pm | ADX?629 Phase 2 Clinical Trial Call |
| 28/11/2023 06:30 pm | Business Update Call |
| 11/07/2023 | SVB Securities Therapeutics Forum |
| 30/06/2023 05:30 pm | Annual General Meeting |
| 29/06/2023 05:30 pm | ADX?2191 Phase 2 Clinical Trial Results Call |
| 27/06/2023 05:30 pm | ADX?629 Phase 2 clinical Trial Results Call |
| 15/06/2023 05:30 pm | INVIGORATE?2 Phase 3 Trial Results Call |
| 09/06/2023 07:00 pm | Jefferies Global Healthcare Conference |
| 04/05/2023 04:30 pm | Q1 2023 Earnings Release |
| 09/03/2023 06:30 pm | Q4 2022 Earnings Call |
| 09/03/2023 05:30 pm | Q4 2022 Earnings Release |
| 16/02/2023 08:30 pm | SVB Securities Global Biopharma Conference |
| 10/11/2022 06:30 pm | Q3 2022 Earnings Call |
| 10/11/2022 05:30 pm | Q3 2022 Earnings Release |
| 26/10/2022 | American Academy of Optometry Meeting |
| 25/10/2022 | American Academy of Optometry Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,43 - | 24,9 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -56,0 -56,5 0.92% | -62,4 -64,3 2.94% | 0,00 -41,0 - | -38,4 |
|
EBIT Million USD | Released Forecast Spread | -63,1 -69,2 8.79% | -36,4 -35,4 -2.95% | -56,2 -57,1 1.52% | -62,7 -67,7 7.42% | -42,8 -46,5 7.96% | -25,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -62,1 -67,7 8.28% | -38,0 -37,0 -2.9% | -57,8 -58,5 1.32% | -62,0 -68,6 9.64% | -37,5 -42,7 12.06% | -19,5 |
|
Net income Million USD | Released Forecast Spread | -60,8 -66,4 8.45% | -37,6 -37,0 -1.6% | -57,8 -58,7 1.5% | -62,0 -68,5 9.39% | -37,5 -40,9 8.26% | -6,64 |
|
EPS USD | Released Forecast Spread | -2,24 -2,42 7.53% | -1,11 -1,09 -1.72% | -1,07 -1,09 1.95% | -1,06 -1,16 8.88% | -0,64 -0,70 7.91% | -0,13 |
| Announcement Date | 12/03/20 | 11/03/21 | 17/03/22 | 09/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,43 - | 1,00 | 0,00 | 0,00 | 15,7 |
|
EBITDA Million USD | Released Forecast Spread | -4,50 | -7,44 | -8,83 | -10,5 | -11,7 | ||||||||
|
EBIT Million USD | Released Forecast Spread | -15,4 -16,3 5.35% | -16,5 -16,5 0.11% | -17,7 -18,1 1.93% | -14,8 -20,8 29.03% | -13,7 -19,3 28.86% | -16,8 -16,8 0.14% | -10,3 -17,9 42.21% | -9,55 -14,6 34.7% | -6,10 -9,80 37.78% | -8,88 | -9,06 | -10,2 | -10,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -15,8 -16,6 5.22% | -16,8 -16,9 0.57% | -17,8 -18,3 2.98% | -14,6 -20,9 30.53% | -12,9 -19,5 33.85% | -15,6 -17,0 8.01% | -8,99 -17,5 48.65% | -8,19 -13,9 40.89% | -4,75 -9,90 51.98% | -8,31 | -8,45 | -9,20 | -9,32 |
|
Net income Million USD | Released Forecast Spread | -15,8 -16,7 5.85% | -16,8 -18,9 11.31% | -17,8 -18,5 4.01% | -14,6 -20,8 29.89% | -12,9 -19,3 33.22% | -15,6 -17,0 8.24% | -8,99 -17,9 49.8% | -8,19 -14,0 41.42% | -4,75 -8,15 41.66% | -6,83 | -8,30 | -9,53 | 22,1 |
|
EPS USD | Released Forecast Spread | -0,27 -0,29 5.97% | -0,29 -0,33 10.96% | -0,30 -0,32 5.26% | -0,25 -0,35 28.57% | -0,22 -0,32 31.61% | -0,27 -0,29 6.36% | -0,15 -0,30 50.55% | -0,14 -0,24 40.85% | -0,08 -0,14 42.17% | -0,11 | -0,14 | -0,16 | 0,27 |
| Announcement Date | 17/03/22 | 05/05/22 | 05/08/22 | 10/11/22 | 09/03/23 | 04/05/23 | 03/08/23 | 03/11/23 | 07/03/24 | - | - | - | - |
| Today 03:30 pm | AURINIA PHARMACEUTICALS INC.: Q1 2024 Earnings Release |
| Today 04:00 pm | SPRINGWORKS THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| Today 04:00 pm | REGENERON PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| Today 04:30 pm | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| Today 08:30 pm | GENMAB A/S: Q1 2024 Earnings Release |
| Today 01:31 am | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 06/05/2024 | FRAZIER LIFESCIENCES ACQUISITION CORPORATION: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | KRYSTAL BIOTECH, INC.: Q1 2024 Earnings Release |
| 06/05/2024 | MERUS N.V.: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | VAXCYTE, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Aldeyra Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALDX Stock
- Calendar Aldeyra Therapeutics, Inc.
